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QuantiFERON-TB Gold In-Tube test to identify latent tuberculosis infection (LTBI). QFT-Plus in-
cludes TB1 and TB2 tubes which contain selected Mycobacterium tuberculosis (Mtb) peptides
designed to stimulate both CD4 and CD8 T-cells. Aim of this study is the flow cytometric char-
acterization of the specific CD4 and CD8 T-cell responses to Mtb antigens contained within QFT-
Plus.
Methods: We enrolled 27 active tuberculosis (TB) patients and 30 LTBI individuals. Following
stimulation with TB1 and TB2, antigen-specific T-cells were characterized by flow cytometry.
Data were also correlated with the grade of TB severity.
Results: TB1 mainly elicited a CD4 T-cell response while TB2 induced both CD4 and CD8 re-
sponses. Moreover, the TB2-specific CD4 response was detected for both active TB and LTBI pa-
tients, whereas the TB2-specific CD8 response was primarily associated with active TB
(p Z 0.01).5582825.
.it (D. Goletti).
.09.008
hed by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under
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CD4/CD8 T-cell responses to QuantiFERON-TB Plus 589Conclusions: To our knowledge, we report the first characterization of the CD4 and CD8 T-cell
response to QFT-Plus. CD8 T-cell response is mainly due to TB2 stimulation which is largely
associated to active TB. These results provide a better knowledge on the use of this assay.
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Tuberculosis (TB), being responsible for 9.6 million cases
and 1.5 million deaths annually, represents a major public
health problem.1 Moreover, latent TB infection (LTBI),
which is estimated to affect one-third of the world’s popu-
lation, may progress to active disease in about 3e15% of the
LTBI individuals during their lifetimes.2,3 Considering that
LTBI subjects are the seedbed of TB disease, diagnosing
and treating LTBI is one of the main goals to control the
TB epidemic.4e7 Tuberculin skin test (TST) and T-cell inter-
feron-g release assays (IGRAs) are the routine diagnostic
tools to identify LTBI. Two IGRAs are commercially avail-
able: the QuantiFERON-TB Gold In-Tube (QFT-GIT) (Qia-
gen, Hilden, Germany) and the T-SPOT.TB (Oxford
Immunotec, Abingdon, UK). IGRAs have several advantages:
the results are not affected by Bacille CalmetteeGue´rin
(BCG)-vaccination4e7 and by the majority of environmental
mycobacteria; moreover, only one patient-visit is required.
However, since these assays are based on an immune
response detection, they have a poor sensitivity in children
and in immune-compromised subjects7e9 furthermore, they
do not discriminate between active TB and LTBI5 and poorly
correlate with the risk of developing active disease.3,10,11
In the last few years several studies have described the
role of CD8 T-cell responses in TB. Mtb-specific CD8 T cells
have been associated with active TB, both in HIV-
uninfected and infected patients,12e15 and to recent infec-
tions, in adults and young children recently exposed to a
smear-positive active TB case.16,17 An increase of the CD8
T-cell responses associates with Mtb load, as found for
both humans and animal models.12,18e20 Importantly, longi-
tudinal studies have shown a decrease of the CD8 T-cell
response during anti-TB treatment.12,13,21
Interestingly, a study on QFT-GIT performance has shown
that the addition of peptides for eliciting CD8 T-cell re-
sponses to QFT-GIT tubes increases the sensitivity of the test
for LTBI detection.22 On the base of this evidence, recently
QuantiFERON-TB Gold Plus (QFT-Plus),23e28 has been pro-
posed as a new generation of QFT-GIT. QFT-Plus includes
two tubes, called TB1 and TB2 respectively, withMycobacte-
rium tuberculosis (Mtb) antigens to elicit a specific immune
response. The TB1 tube, contains peptides derived from
ESAT-6 and CFP-10 (TB-7.7, present in QFT-GIT, has been
removed), and it is designed to induce a specific CD4 T cells
response. TB2 contains newly designed peptides stimulating
interferon (IFN)-g production by both CD4 and CD8 T cells.29
However, as previously described, due to the lack of a gold
standard for LTBI detection, active TB cases are used as sur-
rogate reference standard for evaluating test accuracy.5
At present, the specific response to QFT-Plus TB1 and TB2
tubes has not been characterized. Therefore, the main aim
of this study is to evaluate by flow cytometry the specific CD4and CD8 T-cell responses to the Mtb antigens contained
within the QFT-Plus test in patients with active TB and LTBI.
Materials and methods
Population characteristics
This study was approved by the Ethical Committee of “L.
Spallanzani” National Institute of Infectious Diseases (INMI),
approval number 72/2015. Written informed consent was
required to participate in the study that was conducted at
INMI. We prospectively enrolled HIV-uninfected patients
with pulmonary active TB and LTBI. Active TB microbiolog-
ically diagnosed was defined based on the Mtb isolation from
sputum culture. Active TB clinically diagnosed was defined
based on the clinical and radiological lung lesions associated
with TB in the absence of Mtb isolated in the sputum that
completely recovered after TB-specific treatment for 6
months. Microbiological TB was characterized by first line
Mtb drug-sensitive isolates. Patients were enrolled within 7
days of starting the specific treatment.
In the absence of clinical, microbiological and radiolog-
ical signs of active TB, LTBI was defined based on a positive
score to QFT-GIT (Qiagen, Hilden, Germany). The LTBI
group included subjects with a remote infection (reported
contact with a smear-positive pulmonary TB patient at least
3 years before the enrollment) and subjects reporting a
recent contact (no more than 3 months), LTBI subjects
reporting the time of exposure between “more than 3
months” and “3 years” were not enrolled.30,31 None of the
subjects enrolled had previously undergone treatment with
immunosuppressive drugs. Demographic and epidemiolog-
ical information were collected at enrollment and are re-
ported in Table 1.
Chest X-ray evaluation
All chest X-rays (rendered anonymous) were evaluated for
the presence of nodules, fibrosis, infiltrates, cavitation,
bronchial spread, miliarity, pleural effusion and adenop-
athy, as previously reported.32 Cavity size in centimeters
was recorded (<4 cm, 4 cm). The proportion of the
affected lung was analyzed by a visual estimate of the
extent of parenchymal infiltrates; a proportion of 30% of
affected lung was used as our internal cut-off value to
grade TB severity. In agreement with literature data33 and
on the basis of experience, the disease was graded (by
DG, FP, RU) using a sliding scale of severity as follows: 0:
normal chest X-rays; 1: mild grade (nodules and or infil-
trates with proportion of lung affected <30%); 2: interme-
diate grade (infiltrates with proportion of lung affected
>30% and/or cavitation <4 cm in diameter); 3: high grade
Table 1 Demographic characteristics of enrolled patients.
Active TB Remote LTBI Recent LTBI Total
N (%) 27 (47) 18 (32) 12 (21) 57 (100)
Age Median (IQR) 38 (28e44) 41 (35.7e60.7) 47 (28.5e60.5) 40 (32e51)
Sex
Female N (%) 13 (48) 11 (61) 8 (67) 32 (56)
Origin
West Europe (%) 10 (37) 11 (61) 9 (75) 30 (53)
East Europe (%) 10 (37) 6 (33) 2 (17) 18 (31)
Asia (%) 4 (15) 0 (0) 0 (0) 4 (7)
Africa (%) 2 (7) 1 (6) 1 (8) 4 (7)
South America (%) 1 (4)
BCG
Vaccinated (%) 17 (63) 7 (39) 3 (25) 27 (47)
TB: tuberculosis; LTBI: latent tuberculosis infection; BCG: bacillus CalmetteeGue´rin, IQR: interquartile range.
590 E. Petruccioli et al.(an infiltrate of any percentage of extension with cavitation
>4 cm in diameter and/or bronchial spread and/or miliarity
and/or pleural effusion and/or adenopathy). All subjects
underwent standard chest X-rays at the time of TB
diagnosis.
QFT-GIT and QFT-Plus
QFT-GIT and QFT-Plus assay was performed for each pa-
tient. QFT-Plus kits were donated by Qiagen and used
according to manufacturer’s instructions.29
Levels of IFN-g were quantified by ELISA and the QFT-
Plus Analysis Software (available from www.quantiFERON.
com) was used to analyze raw data and to calculate the re-
sults in international units per milliliter (IU/ml). The soft-
ware performs a quality control assessment of the assay,
generates a standard curve and provides a test result for
each subject. Test results were interpreted according to
manufacturer’s criteria.29
Intracellular staining assay
Intracellular staining (ICS) was performed, concomitantly
to QFT Plus, for each patient. Peripheral blood mono-
nuclear cells (PBMC) were isolated using Ficoll density
gradient centrifugation and resuspended in complete
RPMI-16-40 medium (Gibco, CA, USA) with 10% fetal bovine
serum (PAA Laboratories GmbH, Pasching, Austria). To
characterize by flow cytometry the Mtb-specific T-cell
response, 1  106 PBMC resuspended in 1 ml of medium,
were dispensed in TB1, TB2, Mitogen and Nil tubes of
QFT-Plus kit. After a 1-h incubation, PBMC were transferred
in polystyrene round-bottom tubes, 1 ml/ml of Golgi plug
(BD Biosciences San Jose , USA) was added to inhibit cyto-
kine secretion and anti-CD28 and anti-CD49d monoclonal
antibodies (mAb) at 2 mg/ml each, were added to co-
stimulate cells.
Following an incubation of 16e24 h, the ICS was
performed. As previously described,14,34e36 PBMC were
stained with anti-CD4 peridinin chlorophylprotein (PerCp)-
Cy5.5 conjugate, anti-CD8 allophycocyanin (APC)-H7 conju-
gate, anti-CD3 Horizon V500 conjugate and anti-IFN-g
Pacific Blue (PB) conjugate (all from BD Bioscences). TheMtb-specific T-cell response was characterized evaluating
the frequencies of IFN-g CD4 and IFN-g CD8 T cells
(Fig. 1). At least 200,000 lymphocytes were acquired with
a FACS CANTO II (BD, Bioscences). Cytometry data were
analyzed using FloJo software. Background cytokine pro-
duction in the Nil tube was subtracted from each stimu-
lated condition. If the background was higher than half of
the antigen-specific response, the results were scored as
negative. A frequency of IFN-g-producing T cells of at least
0.03% was considered as positive response.
Statistical analysis
Data were analyzed using SPSS software (Version 19 FOR
Windows, Italy SRL, Bologna, Italy). The median and
interquartile ranges (IQRs) were calculated for continuous
measures. The Chi-Square test was used for proportions.
The KruskaleWallis test was used for comparison among
several groups and the ManneWhitney U test was used for
pairwise comparison. The Spearman rank correlation was
used to correlate continuous variables; rs  0.7 was consid-
ered a high correlation, 0.7 < rs > 0.5 was considered a
moderate correlation and rs  0.5 was considered a low
correlation. The Fisher exact test was used for categorical
variables.
Results
Features of the population
A total of 57 participants were enrolled: 27 with active
pulmonary TB (23 microbiologically diagnosed and 4 clini-
cally diagnosed) and 30 with LTBI (18 remote LTBI and 12
recent LTBI). Fifty-five percent of the enrolled subjects
were from Western Europe; no significant differences were
found for sex, age, origin and BCG vaccination among the
different groups (Table 1).
QFT-Plus evaluation among active TB and LTBI
subjects
QFT-GIT and QFT-Plus assay were performed for each
patient (Fig. 2 and Table 2). To evaluate the sensitivity of
Figure 1 Representative dot plots of the TB2-induced T-cell response of an active TB patient. PBMC were stimulated over-
night with TB1 and TB2 antigens and analyzed by flow cytometry for the intracellular production of IFN-g. The frequency of
Mtb-specific T cells was calculated from the proportions of CD4 IFN-g T cells and CD8 IFN-g T cells.
Figure 2 Evaluation of IFN-g production using QFT-Plus kit. The IFN-g T-cell response was evaluated in active TB patients and
in LTBI subjects with recent and remote infection, one day after whole blood incubation in TB1 and TB2 tubes of the QFT-Plus kit.
Horizontal lines indicate the median. The dotted line represents the cut-off value of 0.35 IU/ml. TB: tuberculosis, LTBI: latent
tuberculosis infection; IU: international unit; IFN: interferon; QFT: QuantiFERON.
CD4/CD8 T-cell responses to QuantiFERON-TB Plus 591
Table 2 Mtb specific response to TB1 and TB2 stimulation in the different groups.
Antigen response to N (%) of responders
Active TB
27 (47)
Remote LTBI
18 (32)
Recent LTBI
12 (21)
Total
57 (100)
QFT-GIT TB antigen 24 (89) 18 (100) 12 (100) 54 (95)
QFT-Plus TB1 21 (78) 18 (100) 12 (100) 51 (89)
TB2 23 (85) 18 (100) 12 (100) 53 (93)
Concomitant
TB1 and TB2
21 (78) 18 (100) 12 (100) 51 (89)
TB1 only 0 (0) 0 (0) 0 (0) 0 (0)
TB2 only 2 (7) 0 (0) 0 (0) 2 (4)
TB1 or TB2 23 (85) 18 (100) 12 (100) 53 (93)
ICS CD4 TB1 22 (81) 17 (94) 12 (100) 51 (89)
TB2 24 (89) 15 (83) 11 (92) 50 (88)
Concomitant
TB1 and TB2
22 (82) 15 (83) 11 (92) 48 (84)
TB1 only 0 (0) 2 (11) 1 (8) 3 (5)
TB2 only 2 (7) 0 (0) 0 (0) 2 (4)
CD8 TB1 4 (15) 3 (18) 4 (33) 11 (19)
TB2 12 (44) 3 (18) 3 (25) 18 (32)
Concomitant
TB1 and TB2
4 (15) 3 (18) 3 (25) 10 (18)
TB1 only 0 (0) 0 (0) 1 (8) 1 (2)
TB2 only 8 (30) 0 (0) 0 (0) 8 (14)
Mtb: Mycobacterium tuberculosis; QFT: QuantiFERON; TB: tuberculosis; LTBI: latent tuberculosis infection; ICS: intracellular staining N:
number.
592 E. Petruccioli et al.the test we used as a surrogate for Mtb infection, the data
generated on active TB patients. Therefore the sensibility
of the tests for Mtb infection in the active TB group was
similar: 89% for QFT-GIT and 85% for QFT-Plus. Among the
active TB patients, the proportion of TB1-responders was
78% whereas for TB2 it was 85% (Table 2). For LTBI subjects,
the proportion of QFT-Plus responders to TB1 and TB2 was
100%, both for recent and remote infection (Table 2). No
significant differences were found comparing the IFN-g pro-
duction to TB1 or TB2 among groups (Fig. 2). All samples
scored positive to the mitogen stimulation.Characterization of the CD4 and CD8 T-cell
responses: evaluation of the proportion of
responders to QFT-Plus by flow cytometry
Our first goal was to compare the CD4 and CD8 T-cell
responses elicited by the same antigen stimulation (Fig. 3).
To assess the specificity of the ICS assay, 10 healthy donors
not exposed to Mtb and scored negative to QFT-Plus, were
enrolled. We found that the specificity of the ICS assay to
detect a TB infection (latent or active TB status) was
100% (data not shown).
Among those with active disease, TB1 induced a CD4-
specific T-cell response in 81% of subjects and a CD8-
specific response in only 15% of them. On the other hand,
TB2 induced a CD4-specific T-cell response in 89% of
subjects and a CD8-specific response in 44% of those
(Fig. 3, Table 2).
Among the remote LTBI subjects, TB1 induced a CD4-
specific T-cell response in 94% and a CD8-specific T cellresponse in only 18% of them (Table 2). The TB2 induced a
CD4-specific T-cell response in 83% of the sample evaluated
and a CD8-specific T cell response in 18% of them (Table 2).
Lastly, for the recent LTBI subjects, TB1 induced a CD4-
specific T-cell response in 100% and a CD8 T-cell response in
33%. After TB2 stimulation we found a CD4-specific T-cell
response in 92% and a CD8 T-cell response in 25% for both,
CD4 and CD8 T-cell subsets (Table 2). Interestingly a
selected CD8 response to TB2 stimulation and not to TB1
was found only in patients with active TB (8 of them)
(Table 2).
These data indicate that TB1 stimulation induces mainly
a CD4 T-cell response in all studied groups, while TB2
stimulation elicits a CD4 response in all groups and a
selective CD8 T-cell response in subjects with active Mtb
replication, either with active disease or with a recent Mtb
exposure.Evaluation of CD4 and CD8 T-cell frequencies to
TB1 and TB2 by flow cytometry
To better characterize the CD8-specific T cells, we evalu-
ated the frequency of the responses to TB1 and TB2. Among
active TB patients, the CD8 response to TB2 was signifi-
cantly higher than that one generated by TB1 (p Z 0.01;
Fig. 3B). Moreover, the active TB group has a frequency of
CD8 response to TB2 stimulation significantly higher
compared to that one elicited in the remote LTBI subjects
(p Z 0.04). These data demonstrate that the Mtb-specific
CD8 T-cell response associates with TB2 stimulation in
active TB patients.
Figure 3 TB2 stimulation induces a CD8 T-cell response in active TB patients. Flow cytometric evaluation of CD4 (A) and CD8
(B) T-cell to TB1 and TB2 antigens in active TB patients and LTBI subjects with recent and remote infection. The response was
scored positive if the frequency of IFN-g producing T cells was at least 0.03%. The horizontal lines represent the medians. Statistical
analysis was performed using the ManneWhitney U test and the p value was considered significant if 0.05. TB: tuberculosis, LTBI:
latent tuberculosis infection.
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CD4 and CD8 T cells in response to the same stimulation. In
LTBI subjects, a significantly higher frequency of the CD4
response to TB1 (p < 0.0001) and TB2 (p Z 0.0005) was
found in comparison to that one generated by CD8 T cells
(Table 3). These data indicate that TB2 stimulation seldom
induces a CD8 response in remote LTBI subjects.Active TB patients showed a significantly higher fre-
quency (p < 0.0001) of TB1-induced CD4 T cells compared
to the levels found for the CD8 T cells. Since TB2
stimulation induced both a CD4 and a CD8 T-cell response
we did not find significant differences comparing the
frequency of the two antigen specific T-cell subsets.
Interestingly, in active TB patients we found a positive
Table 3 Comparison of the frequencies of the CD4 and CD8 T-cell response to TB1 and TB2 in the different groups.
Frequency of the CD4 vs CD8 T-cell response
TB1 TB2
Active TB
p*
Remote LTBI
p*
Recent LTBI
p*
Active TB
p*
Remote LTBI
p*
Recent LTBI
p*
Active TB <0.0001 e e 0.1 e e
Remote LTBI e <0.0001 e e 0.0005 e
Recent LTBI e e 0.02 e e 0.02
Mtb: Mycobacterium tuberculosis; TB: tuberculosis; LTBI: latent tuberculosis infection; p*Z significance according to the ManneWhit-
ney U test.
Significant differences are indicated in bold.
594 E. Petruccioli et al.and significant correlation between the frequencies of CD4
T cells and that one of the CD8 T cells in response to TB2
stimulation (rsZ 0.76, p < 0.0001). These results highlight
the capacity of the cells from active TB patients to respond
with both CD4 and CD8 T-cell subsets to TB2 stimulation.
Impact of the severity of TB disease and
mycobacterial load on QFT-Plus results
Finally, we evaluated whether the severity of TB disease
may influence the response to QFT-Plus. Among the
parameters used to estimate the clinical severity we usedTable 4 Response to TB1 and TB2 stimulation according to the
culture.
Antigen response to Active TB
N (%) of respon
Radiological cla
Low
severity TB
8 (30)
QFT-GIT TB antigen 8 (100)
QFT-Plus TB1 7 (88)
TB2 7 (88)
Concomitant
TB1 and TB2
7 (88)
TB1 only 0 (0)
TB2 only 0 (0)
TB1 or TB2 7 (88)
ICS CD4 TB1 7 (88)
TB2 7 (88)
Concomitant
TB1 and TB2
7 (88)
TB1 only 0 (0)
TB2 only 0 (0)
CD8 TB1 2 (25)
TB2 2 (25)
Concomitant
TB1 and TB2
2 (25)
TB1 only 0 (0)
TB2 only 0 (0)
Mtb: Mycobacterium tuberculosis; QFT: QuantiFERON; TB: tuberculosi
number.the evaluation of the lung lesions based on the radiology
findings. To better analyze the results, the data from
patients with intermediate/high severity (grades 2 and 3)
were combined and compared to those from patients with
low severity (grade 1). As shown in Table 4 the patients with
intermediate/high severity TB had a similar proportion of
responders (84%) to QFT-Plus assay compared to patients
with low TB severity (88%). Analyzing the specific immune
results, CD8 T-cell response to TB2 was found in 53% (10
out 19) of patients with intermediate/high severity TB
and only in 25% (2 out 8) of the low severity TB group
(Table 4, Fig. 4). Moreover stratifying the active TB patientsseverity of active TB and the positivity of the mycobateria
ders
ssification Microbiological classification
Intermediate
high severity TB
19 (70)
Microbiological
confirmed TB
23 (85)
Clinical TB
4 (15)
16 (84) 20 (87) 4 (100)
14 (74) 18 (78) 3 (75)
16 (84) 20 (87) 3 (75)
14 (74) 18 (78) 3 (75)
0 (0) 0 (0) 0 (0)
2 (11) 2 (9) 0 (0)
16 (84) 20 (87) 3 (75)
15 (79) 19 (83) 3 (75)
17 (89) 21 (91) 3 (75)
15 (79) 19 (83) 3 (75)
0 (0) 0 (0) 0 (0)
2 (11) 2 (9) 0 (0)
2 (11) 3 (13) 1 (25)
10 (53) 11 (48) 1 (25)
2 (11) 3 (13) 1 (25)
0 (0) 0 (0) 0 (0)
8 (42) 8 (35) 0 (0)
s; LTBI: latent tuberculosis infection; ICS: intracellular staining, N:
Figure 4 Impact of TB disease severity on CD4 and CD8 T-cell responses. Flow cytometric evaluation of CD4 and CD8 responses
to TB1 and TB2 antigens in active TB patients. Patients were stratified according the grade of TB severity: low and intermediate/
high severity. The bars represent the number of patients responding to TB1 and TB2 stimulation. TB: tuberculosis.
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the TB2-induced CD8 response was associated with a micro-
biological diagnosis of TB more than to a clinical TB diag-
nosis (48% vs 25%) (Table 4). To note that among the
active TB, the CD8 responders either classified as severe
TB (8/10) or by a microbiological diagnosis (8/11), a selec-
tive TB2 response was observed (Table 4). These results
suggest that CD8 T cell response associate with the radio-
logical severity of TB disease and with the mycobacterial
load.
Discussion
This is the first characterization of the CD4 and CD8 T-cell
responses to TB1 and TB2 tubes of QFT-Plus assay in a
cohort of subjects with active TB disease and LTBI enrolled
in a low TB endemic country such as Italy. We demonstrated
that both, TB1 and TB2 induce a CD4 T-cell response. On
the other hand, CD8 T-cell response is mainly due to TB2
stimulation which is largely associated to active TB.
In an effort to find additional tools for performing better
diagnosis using biomarkers,37 the QFT-Plus is a new genera-
tion IGRA designed to offer high sensitivity and specificity
for LTBI diagnosis.29
In the absence of a gold standard for the diagnosis of
LTBI, active TB patients are used as a surrogate to validate
the test. In line with this, a recent study demonstrated that
QFT-Plus, in comparison to QFT-GIT, improves the sensi-
tivity for active TB detection maintaining a high speci-
ficity.23 Other two studies performed in low TB endemic
country demonstrated that the performance of QFT-Plus
is as accurate as that of QFT-GIT.27,28 Here we confirm
that QFT-GIT and QFT-Plus have similar sensitivity for active
TB diagnosis. Moreover in the LTBI population we confirmed
by QFT-Plus the data generated by QFT-GIT.
Several studies have described that CD8 T cells play a
unique function in the recognition and containment of
intracellular infection with Mtb, recognizing and elimi-
nating heavily infected cells38 including cells which do not
belong to the immune system, such as the infected lung
epithelial cells.39 Studies in the mouse model demonstratedthat depletion of CD8 T cells in the chronic stage of Mtb
infection results in increased bacterial burden.40 In vitro
studies have shown that CD8 T cells may kill Mtb-infected
human cells through granule-mediated functions such as
granulysin.41 All these data together indicate that CD8 T
cells are actively involved in the immune response to Mtb
and they are necessary for the control of TB infection.
In the present study only few LTBI subjects showed a CD8
T-cell response. This is in accordance to the literature and
to the concept that latent TB represents a spectrum of
different stages in which the immune system and the
mycobacteria find a host-pathogen equilibrium.42 In this
environment, CD8 T cells are important players to control
the Mtb bacterial load by emerging in the presence of repli-
cating Mtb. This limits bacterial survival,41 but produces tis-
sue damage. Interestingly, the decline of CD8 T-cell
response in parallel with a decrease of Mtb replication
has been described in active TB patients during TB treat-
ment.12,21,43,44 In line with these results, we found lower
CD8-specific responses in clinical TB compared to microbio-
logically diagnosed TB. This highlights that the monitoring
of the CD8 T-cell response to TB2 by flow cytometry can
be a tool to specifically evaluate treatment efficacy. More-
over we also show that TB2-induced CD8 T-cell responses
associate to the grade of TB severity. The result is inter-
esting, although the association did not reach statistical
significance, probably due to the low number of subjects
evaluated. It would be interesting to follow these TB pa-
tients until the end of treatment and evaluate if the CD8-
T cell response change overtime. To note that the TB
patients showing a CD8 response to TB2 stimulation and
not to TB1, have an intermediate high severity TB and are
microbiological confirmed TB, indicating that the Mtb load
and the lung damage influence the ability to respond to
TB2 stimulation. On the other side, independently from
the stimulation tubes considered, we found that the pres-
ence of a CD8 T-cell response is associated to the CD4-
specific response. This relates to the important role that
CD4 T cells play in orchestrating Mtb-specific defense.
According to the manufacturer, TB1 peptides have been
designed to stimulate CD4 T cells while TB2 should elicit
596 E. Petruccioli et al.both CD4 and CD8 responses. Unexpectedly, in the present
study we showed that in a few subjects the CD8 response
was detected also following TB1 stimulation. These sub-
jects, equally spread between all evaluated groups, showed
a concomitant TB2-dependent CD8 T cell-response. This is
probably due to the internalization and processing of the
TB1 peptides by antigen presenting cells and their conse-
quent presentation by the MHC I molecules to CD8 T cells.
Recently, studies using QFT-Plus kit showed that the
difference in IFN-g production between TB2 and TB1
stimulation may provide a surrogate marker of the CD8 T-
cell response magnitude. This difference has been associ-
ated with smear positivity in active TB patients or with a
recent exposure in TB contacts.23 In the present study, us-
ing the same approach, we did not find any association be-
tween these two parameters, probably due to the low
number of recent LTBI subjects enrolled.
In conclusion this is the first report on the characteriza-
tion of the CD4 and CD8 T-cell response to TB1 and TB2
tubes of the QFT-Plus assay. We demonstrated that CD8 T-
cell responses are preferentially induced by TB2 which are
mainly associated to active TB. This assay has the potential
to be very useful in conditions of immune depression
resulting from CD4 T-cell impairments.
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